US2427887A - Analgesic composition - Google Patents
Analgesic composition Download PDFInfo
- Publication number
- US2427887A US2427887A US507455A US50745543A US2427887A US 2427887 A US2427887 A US 2427887A US 507455 A US507455 A US 507455A US 50745543 A US50745543 A US 50745543A US 2427887 A US2427887 A US 2427887A
- Authority
- US
- United States
- Prior art keywords
- analgesic
- composition
- sulfate
- analgesic composition
- phenylisopropylamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title description 20
- 230000000202 analgesic effect Effects 0.000 title description 16
- 239000000150 Sympathomimetic Substances 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 230000001975 sympathomimetic effect Effects 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 230000001754 anti-pyretic effect Effects 0.000 description 5
- 239000002221 antipyretic Substances 0.000 description 5
- 230000003533 narcotic effect Effects 0.000 description 5
- UFUWISIRICUVGE-UHFFFAOYSA-N n-propan-2-ylaniline;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)NC1=CC=CC=C1 UFUWISIRICUVGE-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229960000212 aminophenazone Drugs 0.000 description 2
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 2
- 229940008238 amphetamine sulfate Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- LMVQCWXEXXTIAX-UHFFFAOYSA-N n-methyl-n-propan-2-ylaniline;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)N(C)C1=CC=CC=C1 LMVQCWXEXXTIAX-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
Definitions
- This invention relates to an analgesic composition and, more particularly, to an analgesic composition of the antipyretic type having no narcotic effect.
- composition according to this invention has been found to be of great eflicacy in relievin pain in cases such as headache, toothache, neuralgia, and the like, where analgesics of the antipyretic type having no narcotic effect, as, for example, aspirin and the like, are indicated,
- composition according to this invention involves the combination of an analgesic of the antipyretic type having no narcotic efiect with a sympathomimetic amine, effective to stimulate the sympathetic and central nervous systems, having a structure within the following formula, optical isomers and non-toxic salts thereof:
- the sympathomimetic amines of the group indicated, the optical isomers and non-toxic salts thereof have been long well known and widely used. However, they have not heretofore been suggested or used for analgesic effect, However, despite their lack of any recognized analgesic effect and their well known capacity to stimulate the sympathetic central nervous systems, when administered in admixture with a given dose of an analgesic of the antipyretic type having no narcotic effect, they markedly increase the anal-.
- compositions according to this invention for example, l-phenyl-Z-aminopropane, phenylisopropylmeth- 6 Claims. (Cl. 167-65) 2 ylamine, optical isomers and non-toxic salts thereof, as sulfates, hydrochlorides, and the like, may be used.
- compositions according to this invention may be included inwidely Varying proportion.
- composition may be made up in various forms, as, for example, in a tablet, a solution, a powder or other suitable form.
- the essential ingredients may be extended with any desired excipient, as, for example, sugar or milk, starch, water, or the like, and if desired other ingredients may be included, such, for example, as an effervescent, as sodium bicarbonate and citric acid, or the like where it is desirable to administer the composition in the form of an effervescent drink.
- excipient for example, sugar or milk, starch, water, or the like
- other ingredients such as an effervescent, as sodium bicarbonate and citric acid, or the like where it is desirable to administer the composition in the form of an effervescent drink.
- composition including acetylsalicylic acid and phenylisopropylamine sulfate (amphetamine sulfate),-
- the essential component may be present within about the range:
- Acetylsalicylic acid gm .31.0 Phenylisopropylamine sulfate mgm 5-10 and generally a highly eflicient composition may be made up on any of the following formulae:
- Example 1 Acetylsalicylic acid gm 0.5 Amphetamine sulfate "mgm 5 I
- Example 2 Aminopyrine cm 0,3 d-Phenylisopropylamine sulfate mgm- 2.5
- Example 3 Acetophenetidin ..gm 0.3 d-Phenylisopropylmethylamine sulfate v i A mgm 2.5
- Example 4 Aminopyrine m 0.3 rl-(p-hydroxyphenyl) -2-aminopropane hydrobromide g 20 variously the dosage and form of the composition for administration according to this invention will vary for the individual case and it will be understood that the specific examples given above are not limiting, but are given as illustrative of practical procedure.
- compositions in accordance with this invention using the essential ingredients in proportions within the range indicated, the essential ingredients in powdered form will be admixed, an excipient, as sugar of milk, added and the composition tableted. Again, the ingredients may remain in powdered form or be put in solution for administration. As has been indicated, an effervescent may be added to the end that the composition may be administered in water with efiervescence.
- An analgesic composition comprising in admixture an analgesic of the antipyretic type having no narcotic effect and a component to substantially increase the eflectiveness of the analgesic, said component comprising a non-toxic salt of a sympathomimetic amine having the following formula:
- analgesic composition according to claim 1 characterized by the fact that the analgesic and the non-toxic salt of a sympathomimetic amine are in proportion on the basis of 0.1-1.0 gm. of analgesic to 25-10 mg. of non-toxic salt of asympathomimetic amine.
- An analgesic composition according to claim 1. characterized by the fact that phenylisopropylmethylamine sulfate comprises the non-toxic salt of a sympathomimetic amine.
- a sympathomimetic amine, th acetylsalicylic and phenylisopropylamine sulfate being in proportion on the basis of 0.1-1.0 gm, of acetylsalicylic acid to 25-10 mg. of amine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Patented Sept. 23, 1947 2,427,883] ANALGESIC coMrosrnoN Theodore B. Wallace, Plymouth Meeting, Pa., as-
signor to Smith, Kline & French Laboratories, Philadelphia, Pa., a corporation of Pennsylvania No Drawing. Application October 23,
Serial No. 507,455
This invention relates to an analgesic composition and, more particularly, to an analgesic composition of the antipyretic type having no narcotic effect.
The composition according to this invention has been found to be of great eflicacy in relievin pain in cases such as headache, toothache, neuralgia, and the like, where analgesics of the antipyretic type having no narcotic effect, as, for example, aspirin and the like, are indicated,
The composition according to this invention involves the combination of an analgesic of the antipyretic type having no narcotic efiect with a sympathomimetic amine, effective to stimulate the sympathetic and central nervous systems, having a structure within the following formula, optical isomers and non-toxic salts thereof:
cm-cn-cm I NHR wherein R is a member of the group consisting of H and CH3.
The sympathomimetic amines of the group indicated, the optical isomers and non-toxic salts thereof have been long well known and widely used. However, they have not heretofore been suggested or used for analgesic effect, However, despite their lack of any recognized analgesic effect and their well known capacity to stimulate the sympathetic central nervous systems, when administered in admixture with a given dose of an analgesic of the antipyretic type having no narcotic effect, they markedly increase the anal-.
As illustrative of aromatic sympathomimetic amines contemplatedas an ingredient of compositions according to this invention, for example, l-phenyl-Z-aminopropane, phenylisopropylmeth- 6 Claims. (Cl. 167-65) 2 ylamine, optical isomers and non-toxic salts thereof, as sulfates, hydrochlorides, and the like, may be used.
The essential ingredients of the composition according to this invention may be included inwidely Varying proportion. For administration the composition may be made up in various forms, as, for example, in a tablet, a solution, a powder or other suitable form.
As will be obvious, the essential ingredients may be extended with any desired excipient, as, for example, sugar or milk, starch, water, or the like, and if desired other ingredients may be included, such, for example, as an effervescent, as sodium bicarbonate and citric acid, or the like where it is desirable to administer the composition in the form of an effervescent drink.
Generally speaking, and for practical purposes, the essential ingredients of the composition in accordance with this invention will be combined in proportions within about the broad range:
More specifically with reference to a composition including acetylsalicylic acid and phenylisopropylamine sulfate (amphetamine sulfate),-
the essential component may be present within about the range:
Acetylsalicylic acid gm .31.0 Phenylisopropylamine sulfate mgm 5-10 and generally a highly eflicient composition may be made up on any of the following formulae:
Example 1 Acetylsalicylic acid gm 0.5 Amphetamine sulfate "mgm 5 I Example 2 Aminopyrine cm 0,3 d-Phenylisopropylamine sulfate mgm- 2.5
Example 3 Acetophenetidin ..gm 0.3 d-Phenylisopropylmethylamine sulfate v i A mgm 2.5 Example 4 Aminopyrine m 0.3 rl-(p-hydroxyphenyl) -2-aminopropane hydrobromide g 20 variously the dosage and form of the composition for administration according to this invention will vary for the individual case and it will be understood that the specific examples given above are not limiting, but are given as illustrative of practical procedure.
In making up compositions in accordance with this invention using the essential ingredients in proportions within the range indicated, the essential ingredients in powdered form will be admixed, an excipient, as sugar of milk, added and the composition tableted. Again, the ingredients may remain in powdered form or be put in solution for administration. As has been indicated, an effervescent may be added to the end that the composition may be administered in water with efiervescence.
What I claim and desire to protect by Letters Patent is:
1. An analgesic composition comprising in admixture an analgesic of the antipyretic type having no narcotic effect and a component to substantially increase the eflectiveness of the analgesic, said component comprising a non-toxic salt of a sympathomimetic amine having the following formula:
cm-cn-cm NHR wherein R is a member of the group consisting of H and CH1.
2. An analgesic composition according to claim 1, characterized by the fact that the analgesic and the non-toxic salt of a sympathomimetic amine are in proportion on the basis of 0.1-1.0 gm. of analgesic to 25-10 mg. of non-toxic salt of asympathomimetic amine.
3. An analgesic composition according to claim 1, characterized by the fact that phenylisopropylamine sulfate comprises the non-toxic salt of a sympathomimetic amine.
4. An analgesic composition according to claim 1. characterized by the fact that phenylisopropylmethylamine sulfate comprises the non-toxic salt of a sympathomimetic amine.
a sympathomimetic amine, th acetylsalicylic and phenylisopropylamine sulfate being in proportion on the basis of 0.1-1.0 gm, of acetylsalicylic acid to 25-10 mg. of amine.
THEODORE B. WALLACE.
REFERENCES CITED The following references are of record in the flle of this patent:
UNITED STATES PATENTS Number Name Date 2,350,318 Shonle et al May 30, 1944 OTHER REFERENCES Gutman, Modem Drug Encyc., 2d ed., N. Y., 1941, pp. 56, 205, .228, 349, 507.
Pharmaceutical Abstracts. 1942, p. 98.
Extra Pharmacopoeia-Martindale, 22d ed.
I (1941) in ,2 vols., vol I, pp. 499 to 502.
Sollmann, Manual Pharmacology, 8th ed., 1942, pp. 613, 615, 621, 622, 626, 830.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US507455A US2427887A (en) | 1943-10-23 | 1943-10-23 | Analgesic composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US507455A US2427887A (en) | 1943-10-23 | 1943-10-23 | Analgesic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US2427887A true US2427887A (en) | 1947-09-23 |
Family
ID=24018719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US507455A Expired - Lifetime US2427887A (en) | 1943-10-23 | 1943-10-23 | Analgesic composition |
Country Status (1)
Country | Link |
---|---|
US (1) | US2427887A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2590079A (en) * | 1947-09-23 | 1952-03-25 | Wyeth Corp | Tertiary butyl amines and their preparation |
US2687366A (en) * | 1951-03-20 | 1954-08-24 | American Home Prod | Analgesic composition |
US3082152A (en) * | 1960-04-28 | 1963-03-19 | Stauffer Chemical Co | Adducts of aluminum monohydroxy diacetylsalicylate and ethyl acetoacetate and preparation thereof |
US3253990A (en) * | 1962-01-17 | 1966-05-31 | Mundipharma Ag | N-methyl glucammonium salicylate and uses therefor |
US3352893A (en) * | 1963-02-13 | 1967-11-14 | Chatten Drug & Chem Co | Method of producing hydroxy aluminum disalicylate |
US4083950A (en) * | 1976-03-08 | 1978-04-11 | Miles Laboratories, Inc. | Stable acetylsalicylic acid and phenylpropanolamine salt composition |
US4505862A (en) * | 1981-04-14 | 1985-03-19 | Bristol-Myers Company | Diphenydramine dihydrogencitrate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2350318A (en) * | 1942-04-09 | 1944-05-30 | Lilly Co Eli | Aminoalkanes |
-
1943
- 1943-10-23 US US507455A patent/US2427887A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2350318A (en) * | 1942-04-09 | 1944-05-30 | Lilly Co Eli | Aminoalkanes |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2590079A (en) * | 1947-09-23 | 1952-03-25 | Wyeth Corp | Tertiary butyl amines and their preparation |
US2687366A (en) * | 1951-03-20 | 1954-08-24 | American Home Prod | Analgesic composition |
US3082152A (en) * | 1960-04-28 | 1963-03-19 | Stauffer Chemical Co | Adducts of aluminum monohydroxy diacetylsalicylate and ethyl acetoacetate and preparation thereof |
US3253990A (en) * | 1962-01-17 | 1966-05-31 | Mundipharma Ag | N-methyl glucammonium salicylate and uses therefor |
US3352893A (en) * | 1963-02-13 | 1967-11-14 | Chatten Drug & Chem Co | Method of producing hydroxy aluminum disalicylate |
US4083950A (en) * | 1976-03-08 | 1978-04-11 | Miles Laboratories, Inc. | Stable acetylsalicylic acid and phenylpropanolamine salt composition |
US4505862A (en) * | 1981-04-14 | 1985-03-19 | Bristol-Myers Company | Diphenydramine dihydrogencitrate |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2848556B2 (en) | Cough / cold combination drug containing non-steroidal anti-inflammatory drug | |
JPS61151125A (en) | Dihydrocodeine/ibuprofen drug composition and method | |
ES417377A1 (en) | Salt of S-adenosil-L-methionine and process of preparation | |
GB935601A (en) | Delayed release preparations for asthma therapy containing theophylline | |
US2890984A (en) | Pharmaceutical composition containing 2-(1, 2, 3, 4-tetrahydro-1-naphthyl)imidazo-line | |
Chhetri et al. | Formulation and evaluation of antimicrobial herbal ointment | |
US2427887A (en) | Analgesic composition | |
FI962056A0 (en) | Novel pharmaceutical composition for the preparation of a stable powder containing an active ingredient comprising a combination of acetylsalicylic acid and metoclopramide | |
US4260629A (en) | Treating pain with acetaminophen and 1,4-dimethyl-5-p-chlorobenzoyl-pyrrole-2-acetic acid | |
DE3545201A1 (en) | Synergistic combination of flupirtine and 4-acetamidophenol | |
DK183585A (en) | IMINOTHIAZOLIDE INGREDIENTS, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS THEREOF | |
US3197370A (en) | Pyrilamine tannate compositions | |
GB1011719A (en) | Basic bismuth salt and preparation thereof | |
US1716686A (en) | Pharmaceutical | |
US2668135A (en) | Germ-counteracting compositions | |
KR830008678A (en) | Analgesic composition | |
ATE259778T1 (en) | NON-HYGROSCOPIC SALTS OF ACTIVE INGREDIENTS HAVING THERAPEUTIC AND/OR NUTRITIONAL PROPERTIES AND ORAL COMPOSITIONS CONTAINING SAME | |
JPH0232020A (en) | Method and drug for suppressing manifestation of tolerance in morphine analgestic treatment | |
KR20230090186A (en) | Pharmaceutical composite formulation comprising paracetamol and naproxen | |
US3117910A (en) | Medicinal compositions | |
US2687366A (en) | Analgesic composition | |
US3298915A (en) | Vascular headache treatment | |
US3904765A (en) | Process for controlling lamellar dystrophy of fingernails | |
GB993601A (en) | Antiviral compositions comprising adenine derivatives | |
GB1110397A (en) | Ephedrine composition |